207279-29-6Relevant articles and documents
Synthesis of 4-(8-benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridine-6-yl)-benzoic acid: A potent and selective phosphodiesterase type 4D inhibitor
Hersperger, Rene,Dawson, Janet,Mueller, Thomas
, p. 233 - 235 (2002)
The synthesis of a 6,8-disubstituted 1,7-naphthyridine 1 and its characterization as a potent and selective phosphodiesterase type 4D inhibitor (IC50=1.5nM) are described. The compound inhibited TNFα-release from human peripheral blood mononuclear cells and was orally active in a model of adjuvant-induced arthritis in rats.
INHIBITORS OF PI3 KINASE
-
Page/Page column 129, (2010/01/12)
The present invention relates to compounds of Formula (I), or a pharmaceutically acceptable salt thereof; methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing the compounds, wherein Q, X1, X2, R1 and Z are as defined herein.
Naphthyridine derivatives
-
, (2008/06/13)
PCT No. PCT/EP97/05898 Sec. 371 Date Apr. 27, 1999 Sec. 102(e) Date Apr. 27, 1999 PCT Filed Oct. 24, 1997 PCT Pub. No. WO98/18796 PCT Pub. Date May 7, 1998Novel 8-aryl-1,7-naphthyridines, in free or salt form, are PDE IV inhibitors and are thus useful as pharmaceuticals, e.g. for asthma therapy. Preferred compounds include compounds of formulae (I and II) wherein the R groups are as defined. Pharmaceutical compositions comprising the compounds, processes for preparation of the compounds and novel intermediates for use in the processes are disclosed.